October 2024
Frazier Replenishes Fund with $630 Million for Public Biotech Investments
Frazier, biotech fund, public biotechs, investment, biotechnology
Pharmaceutical Industry Faces Widespread Layoffs Amid Economic Pressures
pharmaceutical layoffs, economic pressures, biopharma industry, job cuts, restructuring efforts
WHO Approves First Mpox Diagnostic Test for Emergency Use: Expanding Global Access to Mpox Testing
WHO, mpox diagnostic test, emergency use, Abbott Molecular, Alinity m MPXV assay, global health emergency, public health efforts
Mendaera Secures $73M Series B Funding to Revolutionize Mainstream Medical Procedures with Robotics and AI
Mendaera, Series B funding, robotics, AI, medical procedures, healthcare technology, Threshold Ventures
Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma
TALVEY (talquetamab), TECVAYLI (teclistamab), Relapsed or Refractory Multiple Myeloma (RRMM), Bispecific Antibody Combination, Extramedullary Disease (EMD), High Response Rates, Durable Responses
Gritstone’s GRANITE Vaccine Shows Encouraging but Limited Benefit in Metastatic Colorectal Cancer
Gritstone bio, GRANITE, cancer vaccine, metastatic colorectal cancer, MSS-CRC, neoantigen targeting immunotherapy, progression-free survival, ctDNA
Gilead Expands HIV Drug Access, Yet Faces Criticism Over Exclusion of Middle-Income Countries
Gilead Sciences, HIV drug access, Lenacapavir, Generic licensing agreements, Middle-income countries exclusion, HIV prevention, Pre-exposure prophylaxis (PrEP)
Resolution Therapeutics Secures £63.5M in Series B Funding to Advance Macrophage Cell Therapy for Liver Disease
Resolution Therapeutics, Series B funding, macrophage cell therapy, liver disease, regenerative medicine, biopharmaceuticals
Kurma Partners Secures €140M for Biofund IV, Aiming for €250M to Fuel European Healthcare Innovation
Kurma Partners, Biofund IV, Healthcare Innovation, Venture Capital, European Biotech, Healthcare Investment
Septerna Embarks on IPO Journey with Promising Preclinical Data and Vision to Revolutionize GPCR Drug Discovery
Septerna, IPO, GPCR, preclinical data, drug discovery, biotechnology, PTH1R agonists, hypoparathyroidism